Clinical usefulness of plasma specimens for detection of nucleophosmin 1 gene mutations in patients with normal karyotype acute myeloid leukemia.
暂无分享，去创建一个
[1] J. Mayer,et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations , 2010, American journal of hematology.
[2] P. Brown,et al. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity , 2009, Hematological oncology.
[3] M. Slovak,et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics , 2008, British journal of haematology.
[4] L. Mariani,et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.
[5] Amber C. Donahue,et al. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. , 2009, Cancer biomarkers : section A of Disease markers.
[6] N. Villamor,et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.